A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults

Starting soon · Phase 1

Conditions studied: Gastritis

In brief

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.

Key facts

Study ID

NCT07717775

Run by

Addpharma Inc.

People needed

30

Starts

2026-08-01

Expected to finish

2026-11-01

Last updated by the study team

2026-07-27

Who can join

Age: 19 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening
• Body weight between 50.0 kg and 90.0 kg, inclusive, and body mass index (BMI) between 18.5 kg/m\^2 and 29.9 kg/m\^2, inclusive, at the time of screening (BMI = weight [kg] / height [m]\^2)
• For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)

You may not qualify if…

• Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration Other exclusions applied

Where it is running

• Seoul National University Hospital, Seoul, — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.